Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/18/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
7662(c) 7722(c) 7645(c) 7650(c) 7777(c) Last
1 167 671 2 530 444 1 950 270 2 126 404 2 462 698 Volume
+0.92% +0.78% -1.00% +0.07% +1.66% Change
More quotes
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Sales 2021 30 409 M - -
Net income 2021 4 577 M - -
Net Debt 2021 11 668 M - -
P/E ratio 2021 29,8x
Yield 2021 2,69%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
More Financials
Company
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows: - oncology (36.8%); - respiratory diseases (22.9%); - cardiovascular, renal and metabolic diseases (18.6%); - other (21.7%): inflammatory and autoimmune diseases, neurological diseases, gastrointestinal and infectious diseases. Net sales are distributed geographically as follows: the United... 
Sector
Pharmaceuticals
Calendar
01/28Presentation
More about the company
Notations Surperformance© of AstraZeneca PLC
Trading Rating : Investor Rating :
More Ratings
All news about ASTRAZENECA PLC
04:52pChina Overtakes U.S. as World's Leading Destination for Foreign Direct Invest..
DJ
03:28pASTRAZENECA : Ecuador approves use of AstraZeneca vaccine for COVID-19
RE
01:23pChina Overtakes U.S. as World's Leading Destination for Foreign Direct Invest..
DJ
01:14pChina Overtakes U.S. as World's Leading Destination for Foreign Direct Invest..
DJ
11:36aPFIZER : UK vaccination drive expands as virus toll nears 100,000
AQ
10:11aASTRAZENECA : Italy to take legal action on COVID vaccine delays to get doses
RE
09:00aASTRAZENECA : Italy to take legal action over COVID vaccine delays to secure dos..
RE
05:24aASTRAZENECA : EU says it will make vaccine companies respect supply contracts - ..
RE
03:21aASTRAZENECA : India to give homegrown vaccine in seven more states this week
RE
01/23THE LATEST : Chicago opens restaurants, some bars with limits
AQ
01/23UK vaccine roll-out speeds up but doctors want quicker second dose
RE
01/23AstraZeneca's Covid-19 Vaccine Shortfall Threatens EU Plans to Boost Inoculat..
DJ
01/23PFIZER : UK doctors seek review of 12-week gap between vaccine doses
AQ
01/23Italy PM says vaccine supply delays are serious contract violations
RE
01/23THE LATEST : N.Y. seniors, churches to get vaccine prep kits
AQ
More news
News in other languages on ASTRAZENECA PLC
10:45aASTRAZENECA : L'Italie poursuit les laboratoires pour sécuriser les doses de vac..
07:09aVERZÖGERUNGEN BEI IMPFSTOFFEN : EU erhöht Druck auf Hersteller
06:08aItaliens Regierungschef kritisiert Impfstoff-Hersteller
05:33aVIRUS : l'Allemagne va utiliser le traitement vanté par Trump
05:05aASTRAZENECA : L'UE fera respecter les contrats de livraison de vaccins, prévient..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Stock Trading Strategies
ASTRAZENECA PLC - 01/18
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 126,47 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,9%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC6.19%139 483
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159